Lung cancer (non-small-cell) - pemetrexed

Summary

• Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small-cell lung cancer.
• People currently receiving pemetrexed should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

Documents

For healthcare professionals

• TA124 Lung cancer (non-small cell) - pemetrexed: Quick reference guide
• TA124 Lung cancer (non-small cell) - pemetrexed: Guidance (MS word format)
• TA124 Lung cancer (non-small cell) - pemetrexed: Guidance

For patients, carers and the public

• TA124 Lung cancer (non-small cell) - pemetrexed: Understanding NICE guidance (MS word format)
• TA124 Lung cancer (non-small cell) - pemetrexed: Understanding NICE guidance

Background information

• 2007/047 NICE issues guidance on pemetrexed (Alimta) for the treatment of non-small-cell lung cancer
• TA124 Lung cancer (non-small cell) - pemetrexed: Distribution list

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• Pemetrexed for the treatment of non-small-cell lung cancer: Costing statement
• Pemetrexed for the treatment of non-small-cell lung cancer: Audit criteria